US Pharma MarketingThe post Labcorp announces colorectal cancer test availability in US appeared first on Medical Device Network.
Labcorp announces colorectal cancer test availability in US
Labcorp has announced the US availability of ColoSense, its FDA-approved RNA-based at-home screening test for colorectal cancer. ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer. ColoSense uses RNA-based methods to detect biomarkers linked to colorectal cancer and advanced adenomas, which are precancerous. Credit: Labcorp / PRNewswire. Labcorp has announced the availability of ColoSense, its ribonucleic acid (RNA)-based at-home screening test for colorectal cancer that has been approved by the US Food and Drug Administration (FDA). Developed by Geneoscopy, the test is being provided commercially through Labcorp following an update…
Labcorp has announced the US availability of ColoSense, its FDA-approved RNA-based at-home screening test for colorectal cancer.
Source: Medical Device Network